EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY-NC-ND 4.0

Serum Galectin-3 as a diagnostic and discriminatory biomarker for chronic kidney disease: A case-control study

Asmaa. H. Nasser, Entedhar Rifaat Sarhat

Journal of Associated Medical Sciences · 24.06.2026 · 59 (3) · 168-176

DOI: 10.66285/jams.2026.090 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Journal of Associated Medical Sciences, online erschienen am 24.06.2026. Verfasst von Asmaa. H. Nasser und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease worldwide. Conventional markers, such as serum creatinine, estimated glomerular filtration rate, and albuminuria, have limited sensitivity for distinguishing among etiologies of advanced chronic kidney disease (CKD) and become abnormal only after substantial nephron loss. Galectin-3 (GAL-3), a beta-galactoside-binding lectin implicated in renal inflammation and fibrosis, has emerged as a candidate biomarker; however, its diagnostic accuracy in distinguishing DKD from non-diabetic CKD in advanced CKD populations remains unclear.

Objective

To quantify serum GAL-3 concentrations in patients with DKD, non-diabetic CKD, and healthy controls, and to evaluate its diagnostic performance in discriminating between these groups in an advanced CKD population. Materials and methods: A case-control study that enrolled 128 participants: 32 patients with DKD (all with type 2 diabetes mellitus), 32 with non-diabetic CKD (both groups on regular hemodialysis classified as CKD stage 5/end-stage renal disease [ESRD]), and 64 healthy controls. Serum GAL-3 levels were measured using an enzyme-linked immunosorbent assay (ELISA). Fasting blood glucose, glycated hemoglobin (HbA1c), renal function tests, and serum albumin levels were assessed using an automated analyzer.

Results

Serum GAL-3 concentrations increased progressively from controls (210.04±34.65 ng/mL) to non-diabetic CKD (262.21±3.19 ng/mL) and then to DKD (368.50±67.10 ng/mL, p

Zitieren

APA

Nasser, A. H., & Sarhat, E. R. (2026). Serum Galectin-3 as a diagnostic and discriminatory biomarker for chronic kidney disease: A case-control study. Journal of Associated Medical Sciences, 59(3), 168-176. https://doi.org/10.66285/jams.2026.090

Vancouver

Nasser AH, Sarhat ER. Serum Galectin-3 as a diagnostic and discriminatory biomarker for chronic kidney disease: A case-control study. Journal of Associated Medical Sciences. 2026;59(3):168-176. doi:10.66285/jams.2026.090

BibTeX
@article{Nasser2026,
  author = {Nasser, Asmaa. H. and Sarhat, Entedhar Rifaat},
  title = {Serum Galectin-3 as a diagnostic and discriminatory biomarker for chronic kidney disease: A case-control study},
  journal = {Journal of Associated Medical Sciences},
  year = {2026},
  volume = {59},
  number = {3},
  pages = {168--176},
  doi = {10.66285/jams.2026.090}
}
Kostenlos starten →